



Company News

Renopharm has received a US patent for its Novel Nitric Oxide Technology.

Nazareth, Israel, the biotechnology company Renopharm Ltd. today announced it has received an Issue Notification, informing that US Patent Application No. **11/266,441** for THIAZOLE-BASED NITRIC OXIDE DONORS HAVING AT LEAST TWO THIAZOLE MOIETIES AND USES THEREOF has been issued as US Patent No. **7,189,750** on **13 March 2007**, and which can now be downloaded from the USPTO website (<http://www.uspto.gov/>).

Contact Information

Dr. Peter Assaf, CEO
Renopharm Ltd.
Nazareth 16000
Israel
Tel.: +972.4.6565.211
Fax:+972.4.6564.129
www.renopharm.com